

Amendment to the Claims

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims

1. (canceled)
2. (canceled)
3. (canceled)
4. (canceled)
5. (canceled)
6. (currently amended) A method for screening a test substance for COX-2 inhibitory activity comprising:
 - (a) contacting the test substance with indicator cells which express a GTPase-deficient mutant form of the α -subunit of protein G12, wherein the G12 protein α -subunit mutant comprises the Q229L mutation, which mutant α -subunit has the capacity to induce the production of arachidonic acid in the indicator cells, and induces production of COX-2 in the indicator cells; and
 - (b) determining the level of one or more prostaglandins produced by the indicator cells in the presence and absence of the test substance, a decrease in production of said prostaglandin by the indicator cells in the presence of the test substance indicating that the test substance has COX-2 inhibitory activity.
7. (canceled)
8. (currently amended) A method according to claim 76 wherein the prostaglandin level is assayed in the media surrounding the indicator cells, in the indicator cells or in a component of the indicator cells.

9. (currently amended) A method according to claim 86 wherein the prostaglandin level is assayed by a prostaglandin immunoassay.

10. (currently amended) A method according to claim 96 wherein the prostaglandin immunoassay comprises a competitive immunoassay.

11. (canceled)

12. (canceled)

13. (canceled)

14. (canceled)